10x Genomics (TXG) Stock Analysis & Winston Score

10x Genomics makes specialized scientific instruments and software that help researchers study individual cells in extreme detail. Their main products — including the Chromium platform for single-cell analysis and the Visium platform for spatial genomics — let scientists see which genes are active inside specific cells and where those cells sit within tissue. Their customers are mostly academic research labs, pharmaceutical companies, and biotech firms trying to understand diseases like cancer. The company sells hardware instruments upfront and then earns recurring revenue from consumables — the chemical reagents and kits researchers must keep buying to run experiments. 10x Genomics operates globally, with a strong presence in North America, Europe, and Asia, and generated roughly $600 million in annual revenue in recent fiscal periods. Its moat comes from proprietary technology and the fact that researchers build entire workflows around its platforms, making switching costly. The key risk is growing competition from rivals like Illumina and smaller startups offering cheaper spatial and single-cell tools.